NCT00002164View on ClinicalTrials.gov

Phase I Study of Safety, Tolerability, and Pharmacokinetics of Viracept in HIV-1 Infected Children and Exposed Infants

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

Not specified

Conditions
HIV Infections
Interventions
DRUG

Nelfinavir mesylate

Trial Locations (1)

90024

UCLA School of Medicine / Dept of Pediatrics, Los Angeles

Sponsors
All Listed Sponsors
lead

Agouron Pharmaceuticals

INDUSTRY

NCT00002164 - Phase I Study of Safety, Tolerability, and Pharmacokinetics of Viracept in HIV-1 Infected Children and Exposed Infants | Biotech Hunter | Biotech Hunter